SUBLOCADE fuels Indivior's growth.
Indivior raises 2026 guidance and announces share buyback amid SUBLOCADE growth.
Anonymous
Key Points
1
Indivior posted an EPS of $5.75 for the quarter, beating estimates by $4.86, with revenue of $343 million versus $307.55 million expected.
2
Total net revenue for Q2 2026 was $358 million, with SUBLOCADE net revenue of $252 million (up 30% year over year) and a 12% rise in dispense unit volume.
3
New patient starts in Q2 2026 were a record at 32,816, and as of June 30, 2026, over 545,000 patients in the U.S. had been prescribed SUBLOCADE since launch.
4
SUBLOCADE now accounts for about 76% of the U.S. long-acting buprenorphine market, underscoring durable demand ahead of the company’s merger with Supernus.
5
An insider, Christian Heidbreder, sold 18,586 Indivior shares for about $764,628 in July, potentially affecting shareholder perception and stock dynamics.
Indivior beat Wall Street expectations in Q2 2026 and raised its full-year guidance, powered by record sales of SUBLOCADE, its injectable treatment for opioid use disorder. Financial Content reported that SUBLOCADE brought in $253 million in net revenue for the quarter, up 30% year over year, while total net revenue hit $358 million.
The company also announced a $400 million share repurchase program and lifted its full-year 2026 sales guidance to a range of $1.295 billion to $1.365 billion, up from a prior range of $1.215 billion to $1.285 billion, according to Benzinga.
Record SUBLOCADE Numbers Drive Q2 Earnings Beat
Indivior posted earnings per share of $5.75 for the quarter, beating analyst estimates by $4.86, according to Watchlist News. Revenue of $343 million also cleared the $307.55 million Wall Street had expected. The strong beat was driven by higher dispense volumes and better-than-expected pricing on SUBLOCADE.
Dispense unit volume for SUBLOCADE rose 12% year over year. New patient starts hit a record 32,816 in the quarter. As of June 30, 2026, more than 545,000 patients in the U.S. had been prescribed SUBLOCADE since the drug launched, per Goldea Capital.
SUBLOCADE Dominates the Long-Acting Buprenorphine Market
SUBLOCADE now holds about 76% of the U.S. long-acting buprenorphine market. Buprenorphine is a medicine that reduces cravings and withdrawal in people with opioid addiction. That dominant share signals durable demand and leaves little room for rivals to close the gap.
247 Wall St. noted that SUBLOCADE saw 21% revenue growth and strong patient uptake during the quarter. Management pointed to continued momentum in patient starts as evidence that the drug is still gaining ground, not just holding it.
Raised 2026 Guidance Signals Management Confidence
Indivior raised its full-year 2026 adjusted EBITDA guidance alongside the revenue upgrade. EBITDA — earnings before interest, taxes, depreciation, and amortization — is a common measure of operating profitability. The updated targets reflect what the company called robust operational execution, according to Financial Content.
The $400 million buyback program shows Indivior is putting cash to work for shareholders. Higher guidance for both revenue and EBITDA together suggest management sees the strong Q2 performance as a trend, not a one-time result.
Supernus Merger Looms as Insider Sells Shares
Indivior is on track to merge with Supernus Pharmaceuticals, with the deal expected to close in Q4 2026. The company described the merger as part of its broader strategic plan, which it calls its "Action Agenda." The tie-up could reshape Indivior's product lineup and market reach.
Not all signals were positive. An insider, Christian Heidbreder, sold 18,586 Indivior shares in July for roughly $764,628. Insider sales can sometimes unsettle investors, though they do not always signal a lack of confidence in the company's direction.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
12
Reach
22
A
AnonymousAuthor